{"article_title": "Hospira Joins Biosimilars Race With FDA Application", "article_keywords": ["fda", "retacrit", "hospira", "epogen", "biosimilars", "epoetin", "application", "race", "york", "joins", "active", "zeta", "biosimilar", "ingredient"], "article_url": "http://www.law360.com/articles/610321/hospira-joins-biosimilars-race-with-fda-application", "article_text": "Hospira Joins Biosimilars Race With FDA Application\n\nLaw360, New York (January 12, 2015, 6:26 PM ET) -- Hospira Inc. announced on Monday that it is asking the U.S. Food and Drug Administration to approve a copycat version of Amgen Inc.\u2019s Epogen and Johnson & Johnson's Procrit, marking the fourth proposed biosimilar along an Affordable Care Act pathway.\n\n\n\nHospira\u2019s product is an anti-anemia biosimilar called Retacrit that European regulators cleared in 2007. Its active ingredient, epoetin zeta, is viewed as comparable to epoetin alfa, the active ingredient in Epogen and Procrit.\n\n\n\nThe Retacrit application was submitted to the FDA on Dec. 16. A spokeswoman...\n\nTo view the full article, register now.", "article_metadata": {"description": "Hospira Inc. announced on Monday that it is asking the U.S. Food and Drug Administration to approve a copycat version of Amgen Inc.&rsquo;s Epogen and Johnson & Johnson&#39;s Procrit, marking the fourth proposed biosimilar along an Affordable Care Act pathway.", "csrf-token": "upl/NIoVjzVxLk+BglatrelG7NVmXPU+VTcLwJdCH+Bg/IflMl8172aDCe3V/OuXaxfXAewJzY85aF3dQ8o6ZA==", "og": {"url": "http://www.law360.com/articles/610321/hospira-joins-biosimilars-race-with-fda-application", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Hospira Joins Biosimilars Race With FDA Application - Law360"}, "csrf-param": "authenticity_token", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/610321/hospira-joins-biosimilars-race-with-fda-application", "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "Its active ingredient, epoetin zeta, is viewed as comparable to epoetin alfa, the active ingredient in Epogen and Procrit.\nThe Retacrit application was submitted to the FDA on Dec. 16.\nHospira Joins Biosimilars Race With FDA ApplicationLaw360, New York (January 12, 2015, 6:26 PM ET) -- Hospira Inc. announced on Monday that it is asking the U.S. Food and Drug Administration to approve a copycat version of Amgen Inc.\u2019s Epogen and Johnson & Johnson's Procrit, marking the fourth proposed biosimilar along an Affordable Care Act pathway.\nHospira\u2019s product is an anti-anemia biosimilar called Retacrit that European regulators cleared in 2007.\nA spokeswoman...To view the full article, register now."}